Want to see SNPHY full AI Analyst Report?
Top Page
Santen Pharmaceutical Co
(OTC:SNPHY)
Select Model
Select Model
Rating:68Neutral
Price Target:
$11.50
â–¼(-3.44% Downside)
Action:Downgraded
Date:08/10/26
The score is driven primarily by solid financial performance: strong profitability, a meaningful earnings recovery, and a low-leverage balance sheet, partly offset by inconsistent operating cash flow conversion and modest margin compression. Technical indicators are mixed with negative near-term momentum, while valuation appears reasonable but not especially compelling.
Positive Factors
Strong Profitability Recovery
Santen has restored consistent profitability after the FY2023 loss, with healthy gross, operating, and net margins. This recovery indicates improved earnings power and provides an internal funding base for product development, commercial investment, and continued expansion across ophthalmology markets.
Negative Factors
Uneven Operating Cash Conversion
Although free cash flow is positive, weak and inconsistent operating cash conversion makes earnings less dependable as a source of internally generated funds. Continued volatility could constrain investment timing and reduce flexibility if product development or commercialization spending rises.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability Recovery
Santen has restored consistent profitability after the FY2023 loss, with healthy gross, operating, and net margins. This recovery indicates improved earnings power and provides an internal funding base for product development, commercial investment, and continued expansion across ophthalmology markets.
Read all positive factors
Santen Pharmaceutical Co (SNPHY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.35B
Dividend Yield2.4%
Average Volume (3M)176.00
Price to Earnings (P/E)13.8
Beta (1Y)0.02
Revenue Growth-3.73%
EPS Growth26.50%
CountryUS
Employees3,968
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)121.85
Shares Outstanding322,314,150
10 Day Avg. Volume0
30 Day Avg. Volume176
Financial Highlights & Ratios
PEG Ratio0.87
Price to Book (P/B)1.94
Price to Sales (P/S)1.87
P/FCF Ratio14.88
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue0.01
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Santen Pharmaceutical Co Business Overview & Revenue Model
Company Description
Santen Pharmaceutical Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, with operations spanning Japan and international markets. The company maintains ...
How the Company Makes Money
Santen primarily makes money by selling ophthalmic pharmaceutical products. Revenue is generated through (1) sales of prescription eye-drop and other ophthalmic medicines to wholesalers, hospitals, clinics, and pharmacies in its core markets (hist...
Santen Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
84
Very Positive
Cash Flow
69
Positive
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 296.76B | 309.21B | 300.00B | 301.96B | 279.04B | 266.26B |
| Gross Profit | 166.48B | 170.68B | 171.03B | 178.71B | 166.09B | 156.59B |
| EBITDA | 66.18B | 67.41B | 59.01B | 50.72B | 12.95B | 52.93B |
| Net Income | 39.34B | 39.62B | 36.26B | 26.64B | -14.95B | 27.22B |
Balance Sheet | ||||||
| Total Assets | 413.10B | 424.87B | 409.28B | 435.70B | 421.18B | 459.98B |
| Cash, Cash Equivalents and Short-Term Investments | 77.74B | 83.35B | 93.99B | 94.96B | 58.68B | 84.31B |
| Total Debt | 30.80B | 34.90B | 34.23B | 35.16B | 36.21B | 32.93B |
| Total Liabilities | 115.81B | 127.57B | 124.10B | 130.33B | 127.88B | 123.13B |
| Stockholders Equity | 298.28B | 298.28B | 286.24B | 306.06B | 293.98B | 337.49B |
Cash Flow | ||||||
| Free Cash Flow | 36.17B | 38.87B | 54.27B | 61.96B | 12.56B | 10.20B |
| Operating Cash Flow | 42.19B | 46.12B | 60.93B | 72.65B | 37.15B | 46.04B |
| Investing Cash Flow | -11.66B | -13.76B | -8.22B | -6.14B | -26.78B | -35.17B |
| Financing Cash Flow | -41.55B | -52.32B | -53.31B | -34.03B | -37.22B | 5.56B |
Santen Pharmaceutical Co Technical Analysis
Negative
11.91
Price Trends
11.60
Negative
11.97
Negative
11.41
Negative
Market Momentum
-0.30
Positive
32.55
Neutral
21.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNPHY, the sentiment is Negative. The current price of 11.91 is above the 20-day moving average (MA) of 11.05, above the 50-day MA of 11.60, and above the 200-day MA of 11.41, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 32.55 is Neutral, neither overbought nor oversold. The STOCH value of 21.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNPHY.
Santen Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $1.08T | 38.24 | 92.58% | 0.58% | 49.58% | 95.08% | |
68 Neutral | $3.35B | 13.82 | 13.39% | 2.40% | -3.73% | 26.50% | |
67 Neutral | $256.80B | 21.30 | 29.64% | 3.36% | 2.33% | -4.08% | |
66 Neutral | $158.45B | 36.73 | 4.89% | 6.19% | -0.21% | -59.71% | |
65 Neutral | $464.43B | 74.04 | -136.50% | 2.60% | 10.39% | 68.16% | |
62 Neutral | $356.01B | 114.52 | 6.60% | 2.36% | 4.51% | -80.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SNPHY
Santen Pharmaceutical Co
10.44
-0.36
-3.36%
LLY
Eli Lilly & Co
1,142.85
303.10
36.09%
MRK
Merck & Company
144.30
58.03
67.27%
NVS
Novartis
141.00
11.29
8.70%
PFE
Pfizer
27.80
3.10
12.56%
ABBV
AbbVie
262.82
39.56
17.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.